Bioventus Inc (BVS)
14.12
+0.54
(+3.98%)
USD |
NASDAQ |
Nov 04, 13:15
Bioventus Enterprise Value: 1.273B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 1.273B |
| October 31, 2024 | 1.273B |
| October 30, 2024 | 1.273B |
| October 29, 2024 | 1.256B |
| October 28, 2024 | 1.239B |
| October 25, 2024 | 1.249B |
| October 24, 2024 | 1.258B |
| October 23, 2024 | 1.254B |
| October 22, 2024 | 1.233B |
| October 21, 2024 | 1.218B |
| October 18, 2024 | 1.232B |
| October 17, 2024 | 1.206B |
| October 16, 2024 | 1.230B |
| October 15, 2024 | 1.218B |
| October 14, 2024 | 1.207B |
| October 11, 2024 | 1.179B |
| October 10, 2024 | 1.122B |
| October 09, 2024 | 1.136B |
| October 08, 2024 | 1.144B |
| October 07, 2024 | 1.118B |
| October 04, 2024 | 1.154B |
| October 03, 2024 | 1.149B |
| October 02, 2024 | 1.156B |
| October 01, 2024 | 1.157B |
| September 30, 2024 | 1.167B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.148B |
| September 26, 2024 | 1.110B |
| September 25, 2024 | 1.147B |
| September 24, 2024 | 1.135B |
| September 23, 2024 | 1.130B |
| September 20, 2024 | 1.162B |
| September 19, 2024 | 1.145B |
| September 18, 2024 | 1.151B |
| September 17, 2024 | 1.131B |
| September 16, 2024 | 1.110B |
| September 13, 2024 | 1.118B |
| September 12, 2024 | 1.101B |
| September 11, 2024 | 1.076B |
| September 10, 2024 | 1.056B |
| September 09, 2024 | 1.074B |
| September 06, 2024 | 1.011B |
| September 05, 2024 | 1.019B |
| September 04, 2024 | 1.019B |
| September 03, 2024 | 1.041B |
| August 30, 2024 | 1.045B |
| August 29, 2024 | 1.033B |
| August 28, 2024 | 1.021B |
| August 27, 2024 | 1.019B |
| August 26, 2024 | 1.040B |
| August 23, 2024 | 1.036B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
508.22M
Minimum
May 04 2023
1.299B
Maximum
Jan 11 2022
805.69M
Average
751.11M
Median
Oct 19 2021
Enterprise Value Benchmarks
| Boston Scientific Corp | 131.03B |
| Insulet Corp | 17.10B |
| Perspective Therapeutics Inc | 524.04M |
| Xtant Medical Holdings Inc | 102.06M |
| Catheter Precision Inc | 2.058M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.99M |
| Revenue (Quarterly) | 151.22M |
| Total Expenses (Quarterly) | 148.42M |
| EPS Diluted (Quarterly) | -0.37 |
| Gross Profit Margin (Quarterly) | 68.54% |
| Profit Margin (Quarterly) | -15.87% |
| Earnings Yield | -4.60% |
| Operating Earnings Yield | 1.64% |
| Normalized Earnings Yield | -1.403 |